Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill (Dialysis-Related Amyloidosis Treatment Act of 2025) amends Medicare (Title XVIII of the Social Security Act) to require coverage and separate payment for FDA-approved treatments for dialysis-related amyloidosis (DRA) furnished in dialysis facilities.
It creates a new definition of “treatments for dialysis-related amyloidosis” to include FDA-approved items and services and necessary adjunct supplies provided in freestanding or hospital-based dialysis facilities.
The bill excludes these treatments from being treated as part of the renal dialysis service bundle under the ESRD prospective payment system and specifies that payment shall be made separately at 100 percent of the reasonable charges for such items and services.
Content alone suggests a reasonably high chance relative to large, ideological, or high‑cost bills because it is narrow, clinically focused, and non‑ideological. That said, the bill's requirement of separate payment at 100% of reasonable charges introduces fiscal exposure and lacks sunset or cost controls, which are the principal risks that could slow or block enactment during budgetary review or amendment.
Relative to its intended legislative type, this bill is a narrowly focused substantive change to Medicare coverage and payment law that is well integrated into existing statutory structure and specifies the fundamental mechanism (definition of covered items and separate payment at 100% of reasonable charges). It leaves significant operational, fiscal, and oversight details to existing administrative processes.
Federal cost and budget impact: liberals and centrists are more willing to accept increased Medicare spending for expanded access, while conservatives emphasize fiscal restraint and offsets.
Federal cost and budget impact: liberals and centrists are more willing to accept increased Medicare spending for expanded access, while conservatives emphasize fiscal restraint and offsets.
A mainstream liberal would likely view the bill positively because it expands Medicare coverage for a specific, often-overlooked condition affecting dialysis patients and guarantees separate payment so providers won’t avoid offering the therapy.
They would appreciate that FDA-approved therapies and necessary adjuncts are explicitly covered, which could improve access and reduce out-of-pocket barriers for vulnerable beneficiaries.
At the same time they would be cautious about cost and price-setting mechanisms and want protections to ensure equitable access, affordability, and oversight of manufacturer pricing.
A mainstream centrist would likely be generally supportive of covering a targeted clinical need while being mindful of federal budget impacts and implementation clarity.
They would see the separate payment as a reasonable fix to avoid perverse incentives in the ESRD bundled payment system, but would want clearer definitions and guardrails to limit unintended cost growth.
Centrists would favor measured oversight, cost estimates, and perhaps a phased implementation or demonstration to monitor clinical benefit and fiscal impact before broad rollout.
A mainstream conservative would be guarded or cautiously skeptical.
They would recognize the bill’s narrow scope and the value of covering an FDA-approved treatment for a specific condition but would be concerned about expanding Medicare spending, potential price inflation, and creating payment exceptions to the ESRD prospective payment system.
The guarantee of payment at 100% of reasonable charges is likely to be viewed as generous and could be seen as weakening payment discipline.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content alone suggests a reasonably high chance relative to large, ideological, or high‑cost bills because it is narrow, clinically focused, and non‑ideological. That said, the bill's requirement of separate payment at 100% of reasonable charges introduces fiscal exposure and lacks sunset or cost controls, which are the principal risks that could slow or block enactment during budgetary review or amendment.
The bill has not accumulated any surfaced votes yet.
Federal cost and budget impact: liberals and centrists are more willing to accept increased Medicare spending for expanded access, while co…
Content alone suggests a reasonably high chance relative to large, ideological, or high‑cost bills because it is narrow, clinically focused…
Relative to its intended legislative type, this bill is a narrowly focused substantive change to Medicare coverage and payment law that is well integrated into existing statutory structure and specifies the fundamental…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.